Psilocybin-assisted therapy could potentially benefit up to 5.6 million Americans with major depressive disorder or treatment ...

People suffering from major depressive disorder (MDD) and treatment-resistant depression (TRD) often face challenging ...

Patients with non-seasonal depression who were treated with bright light therapy reported a 40% remission rate, according to a recent study.

The global major depressive disorder (MDD) treatment market is expected to experience steady growth, projected to develop at ...

(SILO), Monday announced positive results from a pre-clinical study of SPC-15 showing potential for the treatment of major depressive disorder, and other severe stress-related conditions ... severe ...

Major depressive disorder (MDD) is a chronic and recurrent ... of such MDD patients remit following adequate antidepressant treatment, while most MDD patients suffer from significant core ...

Bright light therapy, a standard treatment for seasonal depression, may also help people who experience depression year-round ...

Acupuncture. Ketamine infusions. "Electroshock" or electroconvulsive therapy. The existing treatment options for those ...

TORONTO--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough ...

in addition to treatment, be an effective way to delay or prevent the onset of depressive disorders. Preventing or delaying these disorders may contribute to the further reduction of the disease ...

A recent study published in the Journal of Affective Disorders suggests that a single dose of psilocybin may offer hope for U ...